喀麦隆全国代表性WHO调查后初始HIV耐药流行率
2015年2月至7月在喀麦隆24家随机选取的城乡诊所招募HIV感染者,321条pol序列成功解读;所有起始者中初始耐药(PDR)流行率为10.4%(95%CI 5.4%-19.1%),城市14.2%(95%CI 6.6%-27.9%)高于农村4.3%(95%CI 1.2%-14.3%)。无既往抗逆转录病毒暴露者中PDR总体10.4%(95%CI 4.7%-21.5%),城市13.5%(95%CI 5.1%-31.5%)、农村5.3%(95%CI 1.4%-17.5%)。
要点
- 所有起始者中PDR流行率为10.4%(95%CI 5.4%-19.1%),城市14.2%高于农村4.3%。
- 无既往暴露者中PDR总体10.4%,城市13.5%高于农村5.3%。
- 至少10%的喀麦隆ART起始者携带PDR病毒,可能面临早期ART失败风险。
核心结论
- 喀麦隆至少10%的ART起始者携带初始耐药病毒,可能面临早期ART失败风险。
- NNRTI相关耐药水平高令人担忧,支持引入遗传屏障更高的药物。
研究设计与样本
- 2015年2月至7月从24家随机选取的城乡诊所招募HIV感染ART起始者。
- 采集干血斑标本集中至喀麦隆雅温得参考实验室进行耐药检测。
- 从379名招募者中成功解读321条pol序列,其中城市205条、农村116条。
- 采用斯坦福算法鉴定HIV耐药突变。
主要发现
- 9%(29/321)序列来自报告既往抗逆转录病毒暴露的参与者。
- 所有起始者中PDR流行率为10.4%(95%CI 5.4%-19.1%),城市14.2%(95%CI 6.6%-27.9%)vs 农村4.3%(95%CI 1.2%-14.3%)。
- 无既往暴露者中PDR总体10.4%(95%CI 4.7%-21.5%),城市13.5%(95%CI 5.1%-31.5%)vs 农村5.3%(95%CI 1.4%-17.5%)。
临床怎么用
- 作者认为至少10%的ART起始者携带PDR病毒,可能面临早期ART失败风险。
- 作者认为NNRTI相关耐药水平高令人担忧,支持引入遗传屏障更高的药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretreatment HIV drug resistance (PDR) has the potential to affect treatment outcome and mortality. We present here the first nationally representative PDR study conducted in Cameroon. METHODS: From February to July 2015, HIV-infected ART initiators were recruited from 24 randomly selected clinics situated in both urban and rural regions. Dried blood spot specimens were collected from study participants at these clinics and centralized in a reference laboratory in Yaoundé, Cameroon, for drug resistance testing. HIV drug resistance mutations were identified using the Stanford algorithm. RESULTS: Overall, from the 379 participants recruited, 321 pol sequences were successfully interpreted. Two hundred and five sequences were from patients attending urban ART clinics and 116 from patients seen at rural facilities. Nine percent of sequences (29/321) were from participants reporting previous exposure to antiretrovirals. PDR prevalence among all initiators was 10.4% (95% CI 5.4%-19.1%), with 14.2% (95% CI 6.6%-27.9%) reported in urban areas and 4.3% (95% CI 1.2%-14.3%) in rural areas. Among participants with no prior exposure to antiretrovirals, PDR prevalence was 10.4% (95% CI 4.7%-21.5%) overall, with 13.5% (95% CI 5.1%-31.5%) and 5.3% (95% CI 1.4%-17.5%) reported in urban and rural areas, respectively. CONCLUSIONS: Our findings indicate that at least 10% of patients initiating ART in Cameroon carry viruses with PDR and may be at risk of premature ART failure. The high level of NNRTI-associated resistance is of particular concern and supports introduction of drugs with a higher genetic barrier to resistance.
引用
- Tchouwa GF, Eymard-Duvernay S, Cournil A, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother. 2018. PMID: 29931063. doi:10.1093/jac/dky221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。